Business context and reporting period
This is Homology Medicines, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022—not a filing under the name Q32 Bio Inc. The company is a clinical-stage genetic medicines developer with no product sales. Its programs include HMI-103 for PKU, HMI-203 for Hunter syndrome, HMI-102 for PKU, and HMI-104 for PNH.
Financial performance and position
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $0.8 | $2.2 | $1.6 | $31.5 |
| Research and development expense | $21.1 | $23.7 | $45.3 | $45.5 |
| General and administrative expense | $8.0 | $9.0 | $22.2 | $17.7 |
| Operating loss | $28.3 | $30.6 | $65.9 | $31.7 |
| Net income (loss) | $(29.1) | $(30.5) | $63.0 | $(31.6) |
| Operating cash flow | Not separately presented | Not separately presented | $(61.5) | $(53.9) |
Six-month 2022 net income included a one-time $131.2 million gain on the manufacturing-business transaction with Oxford Biomedica; it does not reflect recurring profitability. The 2021 comparison included $29.9 million of Novartis collaboration revenue recognized following termination of that collaboration. No product revenue was reported. Gross margin is not meaningful for this development-stage business.
At June 30, 2022, cash and cash equivalents were $176.2 million and short-term investments were $49.3 million, totaling $225.5 million. Total assets were $284.6 million, total liabilities $44.3 million, and stockholders’ equity $240.3 million. The company reported no debt. Operating lease liabilities totaled approximately $24.0 million. Management estimated the existing cash, cash equivalents, and short-term investments would fund projected operations into Q4 2024, subject to assumptions and risks.
Material changes versus prior period
- Q2 net loss narrowed by $1.4 million year over year, alongside lower operating expenses and higher interest income, partly offset by a $1.4 million equity-method loss from OXB Solutions.
- Six-month collaboration revenue fell $29.9 million year over year, primarily because Novartis revenue recognized in 2021 did not recur after the collaboration ended.
- Six-month operating expenses rose $4.4 million, as higher G&A expenses—largely transaction-related—offset lower employee-related R&D costs and changes in program spending.
- Cash and investments increased from $155.9 million at December 31, 2021 to $225.5 million at June 30, 2022, primarily reflecting Oxford’s $130.0 million cash payment for the manufacturing business, partly offset by operating cash use.
Outlook, commentary, risks, and unusual items
- On March 10, 2022, Homology transferred manufacturing assets and personnel to OXB Solutions, received $130.0 million, and retained a 20% equity interest. Oxford invested $50.0 million in OXB Solutions. Homology recorded a $131.2 million gain on the transaction.
- Homology expected expenses to decrease overall with pipeline prioritization and cost savings, while spending on HMI-103, HMI-203, and HMI-104 was expected to increase. It also anticipated a modest workforce reduction.
- The filing states that HMI-102’s pheNIX trial was placed on FDA clinical hold in February 2022 over elevated liver-function tests; the FDA lifted the hold on June 13 after the company addressed the issues. In an August 15, 2022 announcement, after quarter-end, Homology said it would pause further enrollment in pheNIX and focus resources on HMI-103. Previously enrolled patients would continue to be monitored.
- HMI-103 was in an open-label Phase 1 dose-escalation trial. The company expected to provide an enrollment and site-status update by year-end 2022; first dosing was contingent on required site approvals and completion of screening/run-in procedures.
- Under its OXB Solutions supply agreement, Homology committed to purchase at least 50% of its clinical AAV-based product supply from OXB Solutions during the initial term, with minimum purchase commitments of approximately $27.5 million in 2022 and $29.7 million in 2023.
- A putative securities class action filed March 25, 2022 alleges inadequate disclosure of HMI-102 trial efficacy and safety information. The company disputes the claims; the case was at an early stage, and any loss was not then determinable or reasonably estimable.
- Management cited continued operating losses, need for future capital, clinical and regulatory uncertainty, dependence on third-party manufacturing, possible COVID-19 disruption, inflation and market volatility as significant risks. The company said it had no committed external source of funds.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Homology Medicines, Inc. (Nasdaq: FIXX), despite the request metadata naming Q32 Bio Inc.
- Assess the assumptions underlying the Q4 2024 cash-runway estimate and the effect of actual spending, clinical progress, and financing needs.
- Track HMI-103 trial initiation, enrollment, safety, and data; HMI-102’s enrollment pause and ongoing patient monitoring; and HMI-203 trial progress.
- Review the OXB Solutions supply commitments, Homology’s 20% investment valuation and performance, and the terms and potential value of the post-three-year buy/sell options, capped at $74.1 million.
- Monitor the securities litigation and any developments in clinical safety, regulatory status, manufacturing supply, or collaboration and licensing arrangements.